MedPath

Clinical Trial News

Pazopanib and Bevacizumab Combination Doubles Survival in Advanced Kidney Cancer

  • A phase 2 clinical trial demonstrated that combining pazopanib and bevacizumab significantly extends progression-free survival in patients with advanced kidney cancer.
  • The combination therapy resulted in a median progression-free survival of 23 months, more than double the 11 months seen with pazopanib alone in previous trials.
  • The treatment regimen showed a favorable safety profile compared to immunotherapy combinations, making it a promising option for patients in the favorable risk group.
  • The study's encouraging results suggest that alternating pazopanib with bevacizumab could be a beneficial treatment strategy for renal cell carcinoma.

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

NCT01684397Active, Not RecruitingPhase 1
Roswell Park Cancer Institute
Posted 11/21/2012

Recent Pipeline Activity: Key Approvals and Phase III Readouts in Pharmaceuticals

  • Recent pharmaceutical pipeline activity reveals four new drug approvals, offering potential advancements in treatment options for various conditions.
  • Multiple Phase III clinical trials have recently reported results, shaping the near-term outlook for several investigational therapies.
  • These developments underscore the dynamic nature of pharmaceutical research and development, highlighting both successes and ongoing efforts to address unmet medical needs.

MinervaX and Wacker Biotech Collaborate to Advance Group B Streptococcus Vaccine Production

  • MinervaX and Wacker Biotech collaborate to scale up manufacturing of MinervaX's novel protein-only vaccine against Group B Streptococcus (GBS) in preparation for Phase III trials.
  • Wacker Biotech will handle technology transfer, process validation, and commercial manufacturing of the vaccine's active protein ingredients at its Amsterdam facility.
  • The GBS vaccine targets maternal immunization to prevent adverse pregnancy outcomes and life-threatening infections in newborns, addressing a critical unmet medical need.
  • MinervaX's vaccine has demonstrated an acceptable safety profile and high immunogenicity in Phase II trials, showing potential for broad protection against GBS.

Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women

NCT05154578CompletedPhase 2
Minervax ApS
Posted 2/17/2022

Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants

NCT05782179CompletedPhase 1
Minervax ApS
Posted 3/1/2023

Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV

NCT04596878CompletedPhase 2
Minervax ApS
Posted 11/19/2020

Expert Highlights Critical Role of Early Diagnosis and Targeted Therapy in BPDCN Management

  • Dr. James Foran of Mayo Clinic emphasizes that BPDCN, often misdiagnosed as other leukemias, requires precise identification of CD123, CD4, and CD56 markers for accurate diagnosis.
  • The FDA-approved CD123-targeted immunotoxin tagraxofusp (Elzonris) has shown promising outcomes in BPDCN treatment, marking a significant advancement in targeted therapy.
  • Early intervention and allogeneic transplantation are crucial for achieving long-term remission and potential cure in BPDCN patients, according to expert insights.

AnaCardio's AC01 Demonstrates Progress in Heart Failure Clinical Trials

  • AnaCardio completed the AC01-FE study in the US, finding AC01 safe and well-tolerated in healthy volunteers under fed and fasted conditions.
  • The phase 1b portion of the GOAL-HF1 study, evaluating AC01 in HFrEF patients, has been successfully completed, showing promising initial results.
  • The GOAL-HF1 study is a randomized, double-blinded, placebo-controlled trial assessing AC01's safety, tolerability, pharmacokinetics, and pharmacodynamic effects.
  • Phase 2a of the GOAL-HF1 study is set to begin in Q1 2025, continuing the evaluation of AC01 as a potential treatment for heart failure.

Immunotherapy Demonstrates Long-Term Survival Benefits in Multiple Cancers

  • Immunotherapy shows promise in achieving long-term survival for advanced melanoma patients, with a 10-year melanoma-specific survival rate of 96% in responsive individuals.
  • In early-stage triple-negative breast cancer, immunotherapy combined with chemotherapy significantly improves the five-year overall survival rate compared to chemotherapy alone.
  • For muscle-invasive bladder cancer, neoadjuvant durvalumab plus chemotherapy leads to longer event-free and overall survival than chemotherapy alone.
  • Ongoing research aims to understand and overcome resistance mechanisms to immunotherapy, fostering collaboration between researchers and pharmaceutical companies.

COVID-19 Hospitalization Linked to Increased Mortality and Functional Decline in Geriatric Patients

  • A multicenter cohort study in Paris found that geriatric patients hospitalized for COVID-19 had significantly higher mortality rates at 18 months post-discharge.
  • COVID-19 patients experienced greater functional decline, impacting their ability to perform daily living activities compared to non-COVID-19 patients.
  • The study highlights the need for tailored follow-up care and rehabilitation strategies for elderly individuals post-COVID-19 hospitalization to mitigate long-term effects.
  • Factors such as age, frailty, and comorbidities significantly influenced mortality, emphasizing the vulnerability of this population to adverse outcomes after COVID-19.

AI-Powered Data Integration Revolutionizes Drug Diversion Detection in Healthcare Systems

  • Healthcare systems face significant challenges in drug diversion detection, with 79% of leaders believing most cases go undetected across multiple facilities and care areas.
  • Advanced AI technology and integrated data feeds are enabling healthcare systems to monitor drug diversion more effectively by analyzing patterns across disparate sources and multiple facilities.
  • A successful drug diversion prevention program combines AI-driven analytics with multidisciplinary collaboration, requiring input from pharmacy, nursing, compliance, and human resources departments.

Alzheimer's Disease and Gene Therapy Clinical Trials Show Promise with Novel Approaches

• Over 120 Alzheimer's Disease treatment therapies are under development globally, targeting various mechanisms of action and routes of administration. • Gene therapy is emerging as a potential treatment strategy, with over 300 gene therapy drugs in the pipeline for various diseases, including neurological disorders. • Several companies are advancing Alzheimer's therapies through clinical trials, including Phase 3 studies for small molecule candidates and Phase 1 trials for novel muscarinic agonists. • Recent FDA approval of Leqembi marks a significant milestone, highlighting the potential of amyloid beta-directed antibodies in treating Alzheimer's disease.

SMA Clinical Trials Update: Investigational Therapies and Expanded Risdiplam Studies

• Several companies are advancing novel therapies for spinal muscular atrophy (SMA), with over 20 treatments currently in clinical development. • Roche is conducting a Phase IV open-label study to assess the effectiveness and safety of risdiplam in pediatric SMA patients following gene therapy. • Biogen is evaluating higher doses of intrathecally administered nusinersen to improve clinical efficacy in SMA patients. • Novartis is studying the safety and efficacy of intrathecal OAV101 in SMA patients who have discontinued nusinersen or risdiplam treatment.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.